<DOC>
	<DOCNO>NCT00189904</DOCNO>
	<brief_summary>The purpose study gather information safety immunogenicity investigational smallpox vaccine HIV infect population .</brief_summary>
	<brief_title>Safety , Tolerability Immune Response IMVAMUNE ( MVA-BN ) Smallpox Vaccine HIV Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Smallpox</mesh_term>
	<criteria>Male subject 18 49 year age female subject 18 55 year age provide informed consent . Women negative pregnancy test . Women childbearing potential must use acceptable method contraception . Cardiac enzymes within ULN . White blood cell ≥ 2500/mm3 &lt; 11,000/ mm3 . Absolute neutrophil count ≥ 1000/mm3 . Adequate renal function . Adequate hepatic function . Negative hepatitis B surface antigen ( HBsAg ) hepatitis B core antibody ( antiHBc ) . Negative antibody test hepatitis C virus ( HCV ) . Negative urine glucose dipstick urinalysis . Normal 12lead electrocardiogram . Availability followup study . Groups 1 3 ( All vaccinianaïve subject ) additionally : No history know suspect previous smallpox vaccination . No detectable vaccinia scar . No military service prior 1989 January 2003 . Groups 2 4 ( All previously vaccinate subject ) additionally : History least one previous smallpox vaccination Time since current smallpox vaccination &gt; 10 year . Groups 1 2 ( All HIV Infected subject ) additionally : Documented HIV1 infection Plasma HIV1 RNA level &lt; 400 copies/mL screening . CD4 cell ≥ 350/µL Haemoglobin ≥ 9.0 g/dL . Platelets ≥ 100,000/mm3 . AST ( SGOT ) , ALT ( SGPT ) alkaline phosphatase ≤ 3 x ULN Groups 3 4 ( All Healthy subject ) additionally : Negative ELISA HIV . Haemoglobin &gt; 11 g/dL . Platelets ≥ 140,000/mm3 . AST ( SGOT ) , ALT ( SGPT ) alkaline phosphatase without clinically significant finding Pregnant breastfeed woman . Uncontrolled serious infection i.e . respond antimicrobial therapy . History serious medical condition ( HIV infection ) . History active autoimmune disease . Known suspected impairment immunologic function ( HIV infection ) . History malignancy . History clinical manifestation clinically significant severe haematological , renal , hepatic , pulmonary , central nervous , cardiovascular gastrointestinal disorder . Clinically significant mental disorder adequately control medical treatment . Any condition might interfere study objective . History coronary heart disease , myocardial infarction , angina , congestive heart failure , cardiomyopathy , stroke transient ischemic attack , uncontrolled high blood pressure , heart condition care doctor . History immediate family member onset ischemic heart disease age 50 . Ten percent great risk develop myocardial infarction coronary death within next 10 year use National Cholesterol Education Program 's risk assessment tool . History chronic alcohol abuse and/or intravenous drug abuse . History allergic disease reaction likely exacerbate component vaccine . Known previous allergic reaction immunoglobulin . Known allergy cidofovir probenecid . History anaphylaxis severe allergic reaction . Acute disease ( illness without fever ) time enrollment . Temperature &gt; 100.4°F time enrollment . Subjects undergoing treatment tuberculosis infection disease . Having receive vaccination plan vaccination live vaccine within 30 day prior study vaccination . Having receive vaccination plan vaccination kill vaccine within 14 day prior study vaccination . Chronic administration immunosuppressant immunemodifying drug . Post organ transplant subject whether receive chronic immunosuppressive therapy . Administration plan administration immunoglobulin and/or blood product . Use investigational nonregistered drug vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>HIV</keyword>
</DOC>